Imlygic
NICE rejects Lilly lung cancer drug, recommends Bayer’s Xofigo and Amgen’s Imlygic
September 30, 2016Medical Communications, Sales and Marketing Imlygic, NICE, Portrazza, xofigo
The National Institute of Health and Care Excellence has issued final guidance rejecting Eli Lilly’s Portrazza (necitumumab) for the treatment …
NICE recommends Amgen’s Imlygic for advanced skin cancer
August 9, 2016Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer
NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults …
Amgen skin cancer drug Imlygic rejected by NICE
March 16, 2016Research and Development Amgen, Imlygic, NICE, melanoma, skin cancer
NICE has rejected Amgen’s drug Imlygic (talimogene laherparepvec) in draft as a treatment for advanced melanoma that has spread and …
European approval for Amgen cancer drug Imlygic
December 18, 2015Sales and Marketing Amgen, European Commission, Imlygic, melanoma, skin cancer, t-vec, talimogene laherparepvec
The European Commission has approved the use of Amgen’s Imlygic for adults with advanced melanoma, making it the first drug …
FDA approves first-in-class Amgen melanoma drug
October 28, 2015Research and Development, Sales and Marketing Amgen, Imlygic, melonoma
The US Food and Drug Administration (FDA) has approved Amgen’s Imlygic for the treatment of melanoma lesions in the skin …
Amgen skin cancer drug gets European approval
October 23, 2015Research and Development Amgen, Imlygic, melanoma, skin cancer
Amgen’s Imlygic (talimogene laherparepvec) has been approved by the scientific committee of the European Medicines Agency (EMA) for the treatment of adults …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
